Validation of High-Performance Low-Field-Strength T1-weighted neuroimaging sequence modelling
Conference paper
WHYNTIE TOM. et al, (2021)
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning.
Journal article
Sirinukunwattana K. et al, (2021), Gut, 70, 544 - 554
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.
Journal article
Malla SB. et al, (2021), Clin Cancer Res, 27, 288 - 300
A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment.
Journal article
Viratham Pulsawatdi A. et al, (2020), Mol Oncol
Fusobacterium nucleatum, rectal cancer and radiotherapy.
Journal article
Mann EH. and Maughan TS., (2020), Ann Oncol
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.
Journal article
Brown NF. et al, (2020), BMC Cancer, 20
Exploration of molecular signalling underpinning the DNA Damage Response Deficiency (DDRD) assay in Colorectal Cancer; Data from the S:CORT consortium (Stratification in COlorRecTal cancer)
Conference paper
Malla S. et al, (2019), BRITISH JOURNAL OF CANCER, 121, 3 - 3
Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.
Journal article
Gray V. et al, (2019), J Natl Cancer Inst, 111, 828 - 836
Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.
Journal article
Hague D. et al, (2019), Trials, 20
Mind the gap? The platform trial as a working environment.
Journal article
Morrell L. et al, (2019), Trials, 20
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
Journal article
Schiavone F. et al, (2019), Trials, 20
Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses.
Journal article
Henderson R. et al, (2019), Oncotarget, 10, 3408 - 3423
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
Journal article
Law PJ. et al, (2019), Nat Commun, 10
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Journal article
McGowan DR. et al, (2019), Eur J Cancer, 113, 87 - 95
Guidelines for using sigQC for systematic evaluation of gene signatures.
Journal article
Dhawan A. et al, (2019), Nat Protoc, 14, 1377 - 1400
Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).
Journal article
Strauss VY. et al, (2019), BMC Cancer, 19
A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours
Conference paper
Wilson R. et al, (2018), EUROPEAN JOURNAL OF CANCER, 103, E140 - E141
Are All Colorectal Oligometastases Equal?
Conference paper
O'Cathail SM. et al, (2018), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 102, E14 - E14
Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.
Journal article
Salem ME. et al, (2018), Eur J Cancer, 103, 205 - 213